Rapiflo 8

Indications:

Rapiflo, a potent selective alpha-1 adrenergic receptor antagonist, effectively alleviates the signs and symptoms of benign prostatic hyperplasia (BPH). It stands out for its superior uroselectivity to alpha-1 adrenergic receptors, making it an optimal choice for those with BPH resistant to Tamsulosin. Unlike some alternatives, Rapiflo doesn’t induce orthostatic hypotension, offering the convenience of once-daily dosing.

Pharmacology:

Silodosin, the active ingredient in Rapiflo, selectively blocks post-synaptic alpha-1 adrenoreceptors in various urinary tract tissues, leading to smooth muscle relaxation. This relaxation enhances urine flow and diminishes BPH symptoms.

Dosage & Administration:

The recommended dosage of Rapiflo is 8 mg orally once daily with food. For individuals with moderate renal impairment (CrCl 30-50 mL/min), the dose is 4 mg taken orally once daily with a meal.

Interaction:

Co-administration of Rapiflo with strong P-glycoprotein inhibitors may elevate plasma concentration. Additionally, combining PDE5 inhibitors with alpha-blockers like Rapiflo can lead to symptomatic hypotension.

Contraindications:

Rapiflo is contraindicated in patients with severe renal and hepatic impairment, those concurrently using strong Cytochrome P450 3A4 (CYP3A4) inhibitors, and individuals with a history of hypersensitivity to Silodosin.

Side Effects:

Common adverse reactions to Rapiflo include retrograde ejaculation, dizziness, diarrhea, headache, and nasal congestion. Notably, orthostatic hypotension may occur.

Pregnancy & Lactation:

Pregnancy Category B. Silodosin isn’t intended for use in women. Studies in animals showed no significant teratogenicity, but caution is advised.

Precautions & Warnings:

Patients initiating Rapiflo treatment may experience postural hypotension, necessitating caution. It should not be used concurrently with other alpha-blockers. Individuals planning cataract surgery should inform their ophthalmologist about Rapiflo usage due to the risk of Intraoperative Floppy Iris Syndrome (IFIS).

Use in Special Populations:

Rapiflo isn’t indicated for pediatric patients. Geriatric use and dosing adjustments for renal and hepatic impairment are outlined based on clinical studies.

Overdose Effects:

In cases of Rapiflo overdose leading to hypotension, cardiovascular support is paramount. Intravenous fluids and vasopressors may be necessary, with careful monitoring of renal function.

Therapeutic Class:

Rapiflo belongs to the therapeutic class of drugs used in benign prostatic hyperplasia, urinary retention, and urinary incontinence.

Storage Conditions:

Store Rapiflo below 30°C in a dry place shielded from light, and ensure it’s inaccessible to children.